The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
The patient has been isolated in a designated hospital and is currently stable
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Subscribe To Our Newsletter & Stay Updated
